You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
SBC: TEZCAT Laboratories LLC Topic: 102Project Summary: Multiple myeloma is an incurable hematologic malignancy with an expected median survival of 7-8 years. The proteasome inhibitors, bortezomib, carfilzomib and the recently approved ixazomib, are a mainstay of current myeloma treatment. Despite an initial response rate approaching 90% to proteasome inhibitor-containing combinations, all patients relapse and eventually become resista ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Genomics MediaBook for a Technology Society
SBC: CENTER LINE PRODUCTIONS Topic: N/ADESCRIPTION (provided by applicant): The Genomics Revolution and the resultant explosion of knowledge in genomics are shaping our futures. Therefore, it is crucial that knowledge of genomics is broadly disseminated, so that future scientists, educators, policy makers, community leaders, and heads of households can harness the beneficial power of genomic science. Given the indiscriminate impact of ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma
SBC: PERIOMICS CARE LLC Topic: 102Abstract Pancreatic ductal adenocarcinoma (PDA) is among the ten most common cancers for both men and women. According to CDC the incidence rates of pancreatic cancer have been rising by almost 1.2% each year over the last 10 years. The 5-year survival rate is less than 7%. Despite the recent success of checkpoint blockade- based monotherapy in human melanoma and non-small cell lung cancer, many P ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors
SBC: NIGHTHAWK BIOSCIENCES, INC. Topic: 102PROJECT SUMMARY Atypical teratoid/rhabdoid tumors (AT/RT) are rare embryonal central nervous system malignancies that occur in early childhood and are lethal. Current treatment strategies for children diagnosed with AT/RT are limited to surgery, radiation, and chemotherapy, but to date, none of these have successfully improved survival beyond 18 months, and most are associated with significant tox ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Validating novel DNA repair deficient cancer therapy targets and small molecule compounds
SBC: ANANEO THERAPEUTICS INC Topic: 102Abstract Single-strand DNA repair (ssDR) is critical for preventing genomic catastrophe. AnaNeo Therapeutics was founded by experts in DNA repair mechanisms. Extending our team’s previous fundamental ssDR studies we analyzed andgt;61,000 tumors for somatic mutations, generated isogenic mutant/wild-type cell line pairs, screened two isogenic cell line pairs with small molecule libraries, performe ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a small-molecule immunomodulator for the treatment of melanoma
SBC: CLARADELE PHARMACEUTICALS, INCORPORATED Topic: NCISUMMARY Melanoma is the most lethal form of skin cancer with treatment costs exceeding $3 billion each year. Melanoma is successfully managed at early stages however, five-year survival rates for the advanced disease are as low as 20%. Immunotherapeutic checkpoint inhibitors (ICI) including agents that target PD1/PD-L1, have substantially improved melanoma survival rates. Unfortunately, only 35-60 ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations
SBC: KITWARE INC Topic: NIBIBDESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based digital health navigation program for colorectal cancer screening
SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC. Topic: 102Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer
SBC: MIRIMUS INC Topic: NCIAbstract Colorectal cancer (CRC) is the third most diagnosed cancer in the USA and accounts for more than 600,000 deaths annually worldwide, primarily due to relapse with highly aggressive, chemo-resistant disease characterized by poorly differentiated cancer cells with stem cell-like properties. A common signature of these chemo-resistant tumors is dysregulation of Notch receptor signaling, as we ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Examination of a novel potential therapy for autonomic dysreflexia
SBC: Dignify Therapeutics LLC Topic: NINDSPROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health